Literature DB >> 21793305

ENOS-G894T polymorphism is a risk factor for essential hypertension in China.

Chen Men1, Kangting Tang, Gang Lin, Jian Li, Yiyang Zhan.   

Abstract

Vascular endothelial cells produce nitric oxide (NO), which contributes to the regulation of blood pressure and regional blood flow. Polymorphisms of the endothelial nitric oxide synthase (eNOS) gene are associated with coronary artery disease; however, associations between polymorphism (G894T) of the eNOS gene and essential hypertension remain unclear. This study was designed to investigate the association between a eNOS-G894T polymorphism and essential hypertension (EH). A total of 190 Chinese EH patients (EH group) and 94 healthy participants (control group) were included in the study. eNOS-G894T was determined using multi-polymerase chain reaction and polymorphisms in eNOS-G894T were genotyped using gene chip technology. Patients carrying eNOS GT + TT genotypes had a higher risk of EH than those carrying the GG genotype (OR = 2.82, 95% CI: 1.05-7.60, P = 0.033). The EH group showed a significantly higher frequency of the T-allele compared with controls (OR = 3.48, 95% CI: 1.34-9.07; P = 0.007). eNOS-894T was found to be significantly associated with EH in the dominant genetic model. Thus, the study demonstrated a significant and independent association between a eNOS-G894T polymorphism and EH in the Chinese patients. The study also showed that eNOS-G894T polymorphism is a risk factor for EH in Chinese patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793305

Source DB:  PubMed          Journal:  Indian J Biochem Biophys        ISSN: 0301-1208            Impact factor:   1.918


  5 in total

1.  Association of endothelial nitric oxide synthase (eNOS) gene G894T polymorphism with hypertension risk and complications.

Authors:  Abeer A ALrefai; Mona Salah El-Din Habib; Rehab I Yaseen; Mahmoud K Gabr; Rabab M Habeeb
Journal:  Mol Cell Biochem       Date:  2016-08-24       Impact factor: 3.396

2.  Methylenetetrahydrofolate reductase C677T gene polymorphism and essential hypertension: A meta-analysis of 10,415 subjects.

Authors:  Ke-Ming Yang; Jian Jia; Li-Na Mao; Chen Men; Kang-Ting Tang; Yan-Yan Li; Hai-Xia Ding; Yi-Yang Zhan
Journal:  Biomed Rep       Date:  2014-06-25

Review 3.  Cardiovascular genomics.

Authors:  Shu-Fen Wung; Kathleen T Hickey; Jacquelyn Y Taylor; Matthew J Gallek
Journal:  J Nurs Scholarsh       Date:  2013-01-31       Impact factor: 3.176

4.  Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase.

Authors:  Erika Salvi; Zoltán Kutalik; Nicola Glorioso; Paola Benaglio; Francesca Frau; Tatiana Kuznetsova; Hisatomi Arima; Clive Hoggart; Jean Tichet; Yury P Nikitin; Costanza Conti; Jitka Seidlerova; Valérie Tikhonoff; Katarzyna Stolarz-Skrzypek; Toby Johnson; Nabila Devos; Laura Zagato; Simonetta Guarrera; Roberta Zaninello; Andrea Calabria; Benedetta Stancanelli; Chiara Troffa; Lutgarde Thijs; Federica Rizzi; Galina Simonova; Sara Lupoli; Giuseppe Argiolas; Daniele Braga; Maria C D'Alessio; Maria F Ortu; Fulvio Ricceri; Maurizio Mercurio; Patrick Descombes; Maurizio Marconi; John Chalmers; Stephen Harrap; Jan Filipovsky; Murielle Bochud; Licia Iacoviello; Justine Ellis; Alice V Stanton; Maris Laan; Sandosh Padmanabhan; Anna F Dominiczak; Nilesh J Samani; Olle Melander; Xavier Jeunemaitre; Paolo Manunta; Amnon Shabo; Paolo Vineis; Francesco P Cappuccio; Mark J Caulfield; Giuseppe Matullo; Carlo Rivolta; Patricia B Munroe; Cristina Barlassina; Jan A Staessen; Jacques S Beckmann; Daniele Cusi
Journal:  Hypertension       Date:  2011-12-19       Impact factor: 10.190

5.  Association of eNOS and Cav-1 gene polymorphisms with susceptibility risk of large artery atherosclerotic stroke.

Authors:  Hann-Yeh Shyu; Ming-Hua Chen; Yi-Hsien Hsieh; Jia-Ching Shieh; Ling-Rong Yen; Hsiao-Wei Wang; Chun-Wen Cheng
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.